HomeCEU Unveils New Continuing Education Packages for Massage Therapists in Florida
HomeCEU, a leader in continuing education (CE) for healthcare professionals with a focus in therapy professions, today announced a series of new CE learning packages for massage therapists in Florida. These courses meet the 24 hours of CE requirements that Florida massage therapists need by August 31, 2025.
'Our philosophy is to make the CEU process quick, easy, and enjoyable, and the new massage therapy packages fit right into our educational approach. Whether you need to complete your full requirements, only need the hands-on learning courses, or want to subscribe to our unlimited membership offerings, we have everything you need to deliver exceptional care to your customers,' said Shane Everett, Vice President and Healthcare Chief Operations Officer at HomeCEU.
HomeCEU's new Florida Massage Therapy CE includes three options: a 24-hour Package to complete the entire Florida Massage Therapy CE requirement, a 12-hour Hands-On Package to complete the hands-on CE requirement, and a Mandatory Course Package that includes required CE topics such as medical errors in the state of Florida.
Florida Massage Therapy Mandatory CE topics include:
All courses are board‑approved and report directly to CE Broker.
'Our educational offerings for massage therapists are streamlined, comprehensive, and compliant—perfect for meeting renewal needs confidently. And our reporting ensures that completed courses appear automatically on each massage therapist's transcript, all as part of our effort to make learning as simple and supported as possible,' continued Everett.
For more information on massage therapy courses to meet the upcoming CE requirements in Florida, visit HomeCEU.com.
ABOUT HOMECEU
HomeCEU is a leading online provider of continuing education and training for professionals in the fields of physical therapy, occupational therapy, speech-language pathology, athletic training, and massage therapy. HomeCEU was founded by former physical therapists who were inspired to fill the gap in the market for quality continuing education options that could be completed at home. HomeCEU helps working professionals meet continuing education needs with convenient continuing education solutions, friendly support, and a relentless dedication to therapy professions. For more information, visit HomeCEU.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250806174420/en/
CONTACT: Jami Cooley
Director of Marketing
[email protected]
800-554-2387
KEYWORD: UNITED STATES NORTH AMERICA FLORIDA
INDUSTRY KEYWORD: HEALTH CONTINUING PHYSICAL THERAPY TRAINING EDUCATION
SOURCE: HomeCEU
Copyright Business Wire 2025.
PUB: 08/06/2025 06:00 AM/DISC: 08/06/2025 06:02 AM
http://www.businesswire.com/news/home/20250806174420/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
3 minutes ago
- CBS News
17 treated after possible chemical spill in Doral, authorities say
A chemical leak at a warehouse near Miami International Mall on Tuesday afternoon sickened 17 people - two of whom were hospitalized - and prompted a large response from Miami-Dade Fire Rescue. Fire officials said about 30 rescue units rushed to the scene on Northwest 19th Street after a call that began as a medical emergency was later upgraded to a hazardous materials incident. Firefighters conducted triage for patients while also working to locate and contain the source of the leak. Seventeen people were treated for mostly respiratory issues, according to Miami-Dade Fire Rescue. Two of those patients were taken to Jackson Memorial Hospital for further care. All of the injuries were described as non-life-threatening. Authorities have not yet identified the chemical that leaked inside the warehouse area. Officials said everyone affected is expected to recover.
Bloomberg
33 minutes ago
- Bloomberg
Walmart Recalls Shrimp From Indonesia Over Radioactive Contamination Fears
Walmart has recalled frozen, raw shrimp sold in 13 states because federal health officials say it could have potential radioactive contamination. The U.S. Food and Drug Administration asked Walmart to pull three lots of Great Value brand frozen shrimp from stores after federal officials detected Cesium-137, a radioactive isotope, in shipping containers and a sample of breaded shrimp imported from Indonesia.
Yahoo
an hour ago
- Yahoo
Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk's breakup with Hims
Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service, are currently soaring after the company announced that it will partner with Novo Nordisk to offer the lowest-ever out-of-pocket prices for Ozempic and Wegovy. Unsold completed new-build inventory is so high this $34B homebuilder is turning to investors 'Job hugging' is the newest career trend: Here's what it means—and why Gen Z is into it Spotify just redesigned the way you'll 'listen' to audiobooks According to a press release posted early on August 18, GoodRx has struck a deal with the pharmaceutical giant Novo Nordisk to sell its popular semaglutide medications, Ozempic and Wegovy, for just $499 per month to 'eligible self-paying customers.' GoodRx doesn't sell or dispense any drugs itself, but rather provides savings and coupons that can be applied in pharmacies. Its exclusive Ozempic and Wegovy offerings, available starting today, are the lowest out-of-pocket costs for the medications available on the market. The news comes just weeks after Novo Nordisk cut ties with the telehealth company Hims & Hers Health (NYSE: HIMS) over claims that Hims & Hers was selling 'knockoff' versions of Wegovy. It's a dispute that reflects a broader discussion around whether compounded semaglutide drugs—or non-FDA approved versions of brand-name medicines—are a violation of intellectual property laws. As of this writing, GoodRx's stock is up by more than 30% since market close. Here's what to know about Novo Nordisk's latest partnership and its ongoing legal battles against compounded GLP-1s. GoodRx's collaboration with Novo Nordisk In the last year alone, GoodRx reports that nearly 17 million people visited the site searching for information and savings on GLP-1 medications—a 22% increase from the previous year. 'Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,' Wendy Barnes, GoodRX president and CEO, said in the press release. 'By partnering with Novo Nordisk, we're taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them.' In the past, a spokesperson told Fast Company, GoodRx has worked with both Novo Nordisk and its competitor Eli Lilly to offer commercially insured patients manufacturer savings cards on GLP-1s. The company has also offered savings on other types of weight loss/diabetes treatments, including Contrave, Dexcom G7, Lantus, and Qsymia. However, this is the first time that GoodRx has offered a cash price for a GLP-1. The $499 monthly self-pay cost will be available at more than 70,000 retail locations nationwide. Novo Nordisk's current legal battles over compounded GLP-1s So far, investors' response to GoodRx's new collaboration has been overwhelmingly positive. It stands in sharp contrast to Hims & Hers' recent breakup with Novo Nordisk, which caused the telehealth company's share prices to plummet in late June. Hims & Hers and Novo Nordisk parted ways over Hims & Hers' offering of compounded versions of Wegovy. Back in 2022, the Food and Drug Administration (FDA) declared a shortage of GLP-1 medications including Ozempic and Wegovy. Under this shortage notice, pharmacies were permitted to make compounded versions of the brand-name drugs using their active ingredient, semaglutide, and sell them at a lower cost. However, Hims & Hers has continued to sell its compounded version of Wegovy long after the FDA lifted the shortage back in February. Now, Novo Nordisk is arguing that these compounded drugs are both a violation of its intellectual property and potentially dangerous to patients, due to their lack of FDA approval. Early this month, Novo Nordisk announced 14 new lawsuits against small pharmacies, telehealth providers, and weight-loss clinics over compounded versions of Ozempic and Wegovy—bringing its total cases filed on the matter up to more than 130 in 40 states. Experts say that federal compounding laws are just vague enough to allow for various interpretations, meaning that Novo Nordisk's current legal challenges could shape the way courts interpret those boundaries in the future. In a statement to Yahoo Finance, Barnes offered a clear look into GoodRx's stance on compounded drugs: 'There's no question we could have tried to do something sooner from a compounded alternative pathway, but we have been very clear in our belief that it needed to be FDA-approved, lawfully approved. It just wasn't a pathway that we were going to support,' she said. This post originally appeared at to get the Fast Company newsletter:
